Analytical testing can make or break a drug program. Integrated, in-house testing strategies offer faster turnaround times, stronger quality oversight, and greater flexibility—helping sponsors stay on track, reduce risk, and maintain data integrity from clinical through commercial stages. While outsourcing may support specialized needs, relying on multiple vendors can introduce delays, complexity, and added risk.
To read the full article, click the link below.
At this year’s NYC Awards Night, we had the privilege of recognizing several exceptional leaders advancing innovation across healthcare technology.
Congratulations to Jenn Adams, CEO of August Bioservices, on being named Healthcare Technology CEO of the Year.
Jenn has led August Bioservices since its founding in 2020, building a contract development and manufacturing organization (CDMO) dedicated to sterile injectable therapies. Headquartered in Nashville, the company provides development and manufacturing services that help drug developers advance innovative therapies from early development through commercialization.
Accepting the award, Jenn shared: “When we started our company five and a half years ago, we had a really clear goal and we set out to build a CDMO focused on sterile injectables that could truly serve as a partner to our clients, providing deep technical expertise and a state-of-the-art facility and equipment — all designed to help advance innovative therapies through development and commercialization. Our aspiration is to show up so fully for our clients that they cannot tell the difference anymore. It’s indistinguishable to them who is on their team and who is on our team because we’re working shoulder to shoulder to make sure the drug is advanced. And then we’re bridging the innovation and bringing it to patients who need that innovation in the form of therapies.”
Picture: Jenn Adams speaks at NYC Awards Night
Read full Article here:https://thehealthcaretechnologyreport.com/jenn-adams-named-healthcare-technology-ceo-of-the-year/
Click the link to see Jason Hartman and Michael Scribner share valuable insights into our collaboration with Optima. ✅ Why Optima’s equipment was the perfect fit for our specific requirements ✅ How Optima’s Turnkey approach and the flexibility of its solutions created real added value ✅ What truly matters when building a strong, reliable, and successful partnership with Optima, we believe that close collaboration and a deep understanding of customer needs are the foundation for delivering innovative, tailored solutions that empower our partners to grow and succeed.
The Healthcare Technology Report’s Top 50 Healthcare Technology Companies of 2025 spotlights how quickly healthcare innovation is expanding across diagnostics, care delivery, clinical intelligence, and data-driven precision medicine, highlighting major breakthroughs from companies as the industry pushes toward faster, smarter, and more scalable solutions. August Bioservices was nominated as one of the key companies recognized this year, reinforcing the growing importance of advanced biomanufacturing in the healthcare technology ecosystem and underscoring August’s role in helping bring next-generation therapies from development to patients with speed, flexibility, and quality.
Intellectual property powers lifesaving innovations and therapies
Exploring innovations, challenges, and future horizons in parenteral drug delivery.
For this roundtable, Contract Pharma called upon thought leaders across the pharmaceutical services sector to address “3 Key Trends” impacting the CDMO industry in 2025 and beyond.
Bringing a sterile injectable product from development to commercialization requires a seamless scale-up process—one that minimizes risk, optimizes efficiency, and ensures regulatory success. In this exclusive webinar, experts from August Bioservices will discuss the critical factors that make or break a successful scale-up, sharing insights from a CDMO’s unique perspective.
CDMO leaders talk about navigating a dynamic landscape of innovation and demand.
